Inovio initiates DNA immunotherapy trial for breast, lung and pancreatic cancers
Inovio announced it has initiated a phase I trial of its hTERT DNA immunotherapy alone or in combination with Inovio's IL-12 immune activator in adults with breast, lung, or pancreatic cancer at high risk of relapse after surgery and other cancer treatments. December 18, 2014